Genentech Dismisses BPCIA Suit Over Perjeta Biosimilar Pebrilzo

Genentech voluntarily dismissed its BPCIA patent litigation against Biocon concerning the proposed Perjeta (pertuzumab) biosimilar Pebrilzo on October 14, 2026, though the source does not disclose whether a settlement was reached.